Combined neuropeptide S and D-cycloserine augmentation prevents the return of fear in extinction-impaired rodents: Advantage of dual versus single drug approaches

International Journal of Neuropsychopharmacology

Volumn 19, Issue 6, 2016, Pages 1-11

  Sartori, Simone B ^a   Maurer, Verena ^a   Murphy, Conor ^a   Schmuckermair, Claudia ^a   Muigg, Patrick ^a   Neumann, Inga D ^b   Whittle, Nigel ^a   Singewald, Nicolas ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

D cycloserine; Fear extinction; Fear relapse; Neuropeptide S; Renewal

Indexed keywords

BENZODIAZEPINE; CYCLOSERINE; NEUROPEPTIDE S; ANXIOLYTIC AGENT; NEUROPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE RE-EMERGENCE; DRUG EFFICACY; ELEVATED PLUS MAZE TEST; FEAR; FOOTSHOCK; FREEZING; LATERAL BRAIN VENTRICLE; LIGHT DARK CYCLE; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; 129 MOUSE; ANIMAL; ANIMAL BEHAVIOR; ANXIETY; COGNITION; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CONDITIONED REFLEX; DISEASE MODEL; DRUG EFFECTS; GENETICS; IMPLOSIVE THERAPY; INBRED RAT STRAIN; PROCEDURES; PSYCHOLOGY; RECURRENT DISEASE; REINFORCEMENT; THERAPY; TIME FACTOR;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; COGNITION; CONDITIONING, CLASSICAL; CYCLOSERINE; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; EXTINCTION, PSYCHOLOGICAL; FEAR; IMPLOSIVE THERAPY; MALE; MICE, 129 STRAIN; NEUROPEPTIDES; RATS, INBRED STRAINS; RECURRENCE; TIME FACTORS;

EID: 84979787957     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyv128     Document Type: Article

References (72)

1. Abramowitz JS (2013) The practice of exposure therapy: relevance of cognitive-behavioral theory and extinction theory. Behav Ther 44:548-558.
2. Adori C, Barde S, Vas S, Ebner K, Su J, Svensson C, Mathe AA, Singewald N, Reinscheid RR, Uhlen M, Kultima K, Bagdy G, Hokfelt T (2015) Exploring the role of neuropeptide S in the regulation of arousal: a functional anatomical study. Brain Struct Funct 13 Oct:1-26.
3. Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, Moller HJ (2012) Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract 16:77-84.
4. Birk L (2004) Pharmacotherapy for performance anxiety disorders: occasionally useful but typically contraindicated. J Clin Psychol 60:867-879.
5. Blanchard RJ, Blanchard DC (1969) Passive and active reactions to fear-eliciting stimuli. J Comp Physiol Psychol 68:129-135.
6. Bouton ME, Kenney FA, Rosengard C (1990) State-dependent fear extinction with two benzodiazepine tranquilizers. Behav Neurosci 104:44-55.
7. Bouton ME, Vurbic D, Woods AM (2008) D-cycloserine facilitates context-specific fear extinction learning. Neurobiol Learn Mem 90:504-510.
8. Bustos SG, Maldonado H, Molina VA (2009) Disruptive effect of midazolam on fear memory reconsolidation: decisive influence of reactivation time span and memory age. Neuropsychopharmacology 34:446-457.
9. Camp M, Norcross M, Whittle N, Feyder M, D'Hanis W, Yilmazer-Hanke D, Singewald N, Holmes A (2009) Impaired Pavlovian fear extinction is a common phenotype across genetic lineages of the 129 inbred mouse strain. Genes Brain Behav 8:744-752.
10. Camp MC, Macpherson KP, Lederle L, Graybeal C, Gaburro S, Debrouse LM, Ihne JL, Bravo JA, O'Connor RM, Ciocchi S, Wellman CL, Luthi A, Cryan JF, Singewald N, Holmes A (2012) Genetic strain differences in learned fear inhibition associated with variation in neuroendocrine, autonomic, and amygdala dendritic phenotypes. Neuropsychopharmacology 37:1534-1547.
11. Chauveau F, Lange MD, Jungling K, Lesting J, Seidenbecher T, Pape HC (2012) Prevention of stress-impaired fear extinction through neuropeptide s action in the lateral amygdala. Neuropsychopharmacology 37:1588-1599.
12. Choy Y, Fyer AJ, Lipsitz JD (2007) Treatment of specific phobia in adults. Clin Psychol Rev 27:266-286.
13. Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF, 3rd (2013) The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons. World psychiatry: official journal of the World Psychiatric Association 12:137-148.
14. Dannlowski U, Kugel H, Franke F, Stuhrmann A, Hohoff C, Zwanzger P, Lenzen T, Grotegerd D, Suslow T, Arolt V, Heindel W, Domschke K (2011) Neuropeptide-S (NPS) receptor genotype modulates basolateral amygdala responsiveness to aversive stimuli. Neuropsychopharmacology 36:1879-1885.
15. Davis M, Ressler K, Rothbaum BO, Richardson R (2006) Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry 60:369-375.
16. de Kleine RA, Smits JA, Hendriks GJ, Becker ES, van Minnen A (2015) Extinction learning as a moderator of d-cycloserine efficacy for enhancing exposure therapy in posttraumatic stress disorder. J Anxiety Disord 34:63-67.
17. Dine J, Ionescu IA, Avrabos C, Yen YC, Holsboer F, Landgraf R, Schmidt U, Eder M (2015) Intranasally applied neuropeptide S shifts a high-anxiety electrophysiological endophenotype in the ventral hippocampus towards a "normal"-anxiety one. PLoS One 10:e0120272.
18. Domschke K et al. (2011) Neuropeptide S receptor gene - converging evidence for a role in panic disorder. Mol Psychiatry 16:938-948.
19. Donner J et al. (2010) Assessment of the neuropeptide S system in anxiety disorders. Biol Psychiatry 68:474-483.
20. Farrell NR, Deacon BJ, Dixon LJ, Lickel JJ (2013) Theory-based training strategies for modifying practitioner concerns about exposure therapy. J Anxiety Disord 27:781-787.
21. Flood JF, Morley JE, Lanthorn TH (1992) Effect on memory processing by D-cycloserine, an agonist of the NMDA/glycine receptor. Eur J Pharmacol 221:249-254.
22. Foa EB, Kozak MJ (1986) Emotional processing of fear: exposure to corrective information. Psychol Bull 99:20-35.
23. Glotzbach-Schoon E, Andreatta M, Reif A, Ewald H, Troger C, Baumann C, Deckert J, Muhlberger A, Pauli P (2013) Contextual fear conditioning in virtual reality is affected by 5HTTLPR and NPSR1 polymorphisms: effects on fear-potentiated startle. Front Behav Neurosci 7:31.
24. Goldman MS (1977) Effect of chlordiazepoxide administered early in extinction on subsequent extinction of a conditioned emotional response in rats: implications for human clinical use. Psychol Rep 40:783-786.
25. Goode TD, Maren S (2014) Animal models of fear relapse. ILAR journal / National Research Council, Institute of Laboratory Animal Resources 55:246-258.
26. Graham BM, Richardson R (2009) Acute systemic fibroblast growth factor-2 enhances long-term extinction of fear and reduces reinstatement in rats. Neuropsychopharmacology 34:1875-1882.
27. Graham BM, Richardson R (2010) Fibroblast growth factor-2 enhances extinction and reduces renewal of conditioned fear. Neuropsychopharmacology 35:1348-1355.
28. Graham BM, Milad MR (2011) The study of fear extinction: implications for anxiety disorders. Am J Psychiatry 168:1255-1265.
29. Gunduz-Cinar O, MacPherson KP, Cinar R, Gamble-George J, Sugden K, Williams B, Godlewski G, Ramikie TS, Gorka AX, Alapafuja SO, Nikas SP, Makriyannis A, Poulton R, Patel S, Hariri AR, Caspi A, Moffitt TE, Kunos G, Holmes A (2013) Convergent translational evidence of a role for anandamide in amygdalamediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry 18:813-823.
30. Han RW, Zhang RS, Xu HJ, Chang M, Peng YL, Wang R (2013) Neuropeptide S enhances memory and mitigates memory impairment induced by MK801, scopolamine or Abeta(1)(-)(4) (2) in mice novel object and object location recognition tasks. Neuropharmacology 70:261-267.
31. Hart G, Panayi MC, Harris JA, Westbrook RF (2014) Benzodiazepine treatment can impair or spare extinction, depending on when it is given. Behav Res Ther 56:22-29.
32. Hefner K, Whittle N, Juhasz J, Norcross M, Karlsson RM, Saksida LM, Bussey TJ, Singewald N, Holmes A (2008) Impaired fear extinction learning and cortico-amygdala circuit abnormalities in a common genetic mouse strain. J Neurosci 28:8074-8085.
33. Herry C, Johansen JP (2014) Encoding of fear learning and memory in distributed neuronal circuits. Nat Neurosci 17:1644-1654.
34. Hofmann SG, Sawyer AT, Korte KJ, Smits JA (2009) Is it beneficial to add pharmacotherapy to cognitive-behavioral therapy when treating anxiety disorders? A meta-analytic review. Int J Cogn Ther 2:160-175.
35. Hofmann SG, Wu JQ, Boettcher H (2013) D-Cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders. Biol Mood Anxiety Disord 3:11.
36. Holmes A, Singewald N (2013) Individual differences in recovery from traumatic fear. Trends Neurosci 36:23-31.
37. Jungling K, Seidenbecher T, Sosulina L, Lesting J, Sangha S, Clark SD, Okamura N, Duangdao DM, Xu YL, Reinscheid RK, Pape HC (2008) Neuropeptide S-mediated control of fear expression and extinction: role of intercalated GABAergic neurons in the amygdala. Neuron 59:298-310.
38. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617-627.
39. Land C, Riccio DC (1999) d-Cycloserine: effects on long-term retention of a conditioned response and on memory for contextual attributes. Neurobiol Learn Mem 72:158-168.
40. Leonard SK, Dwyer JM, Sukoff Rizzo SJ, Platt B, Logue SF, Neal SJ, Malberg JE, Beyer CE, Schechter LE, Rosenzweig-Lipson S, Ring RH (2008) Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders. Psychopharmacology (Berl) 197:601-611.
41. Lukas M, Neumann ID (2012) Nasal application of neuropeptide S reduces anxiety and prolongs memory in rats: social versus non-social effects. Neuropharmacology 62:398-405.
42. MacKillop J, Few LR, Stojek MK, Murphy CM, Malutinok SF, Johnson FT, Hofmann SG, McGeary JE, Swift RM, Monti PM (2015) D-cycloserine to enhance extinction of cue-elicited craving for alcohol: a translational approach. Translational psychiatry 5:e544.
43. Meis S, Bergado-Acosta JR, Yanagawa Y, Obata K, Stork O, Munsch T (2008) Identification of a neuropeptide S responsive circuitry shaping amygdala activity via the endopiriform nucleus. PLoS One 3:e2695.
44. Milad MR, Furtak SC, Greenberg JL, Keshaviah A, Im JJ, Falkenstein MJ, Jenike M, Rauch SL, Wilhelm S (2013) Deficits in conditioned fear extinction in obsessive-compulsive disorder and neurobiological changes in the fear circuit. JAMA psychiatry 70:608-618; quiz 554.
45. Monahan JB, Handelmann GE, Hood WF, Cordi AA (1989) D-cycloserine, a positive modulator of the N-methyl-D-aspartate receptor, enhances performance of learning tasks in rats. Pharmacol Biochem Behav 34:649-653.
46. Morris RW, Bouton ME (2007) The effect of yohimbine on the extinction of conditioned fear: a role for context. Behav Neurosci 121:501-514.
47. Muigg P, Hetzenauer A, Hauer G, Hauschild M, Gaburro S, Frank E, Landgraf R, Singewald N (2008) Impaired extinction of learned fear in rats selectively bred for high anxiety-evidence of altered neuronal processing in prefrontal-amygdala pathways. Eur J Neurosci 28:2299-2309.
48. Neumann ID, Veenema AH, Beiderbeck DI (2010) Aggression and anxiety: social context and neurobiological links. Front Behav Neurosci 4:12.
49. Okamura N, Hashimoto K, Iyo M, Shimizu E, Dempfle A, Friedel S, Reinscheid RK (2007) Gender-specific association of a functional coding polymorphism in the Neuropeptide S receptor gene with panic disorder but not with schizophrenia or attention-deficit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 31:1444-1448.
50. Okamura N, Garau C, Duangdao DM, Clark SD, Jungling K, Pape HC, Reinscheid RK (2011) Neuropeptide S enhances memory during the consolidation phase and interacts with noradrenergic systems in the brain. Neuropsychopharmacology 36:744-752.
51. Olatunji BO, Cisler JM, Deacon BJ (2010) Efficacy of cognitive behavioral therapy for anxiety disorders: a review of metaanalytic findings. Psychiatr Clin North Am 33:557-577.
52. Paxinos KBL, Franklin G (2001) The mouse brain in stereotaxic coordinates. 2nd Ed. In. London: Academic Press. Pereira ME, Rosat R, Huang CH, Godoy MG, Izquierdo I (1989) Inhibition by diazepam of the effect of additional training and of extinction on the retention of shuttle avoidance behavior in rats. Behav Neurosci 103:202-205.
53. Pitkanen M, Sirvio J, MacDonald E, Niemi S, Ekonsalo T, Riekkinen P, Sr. (1995) The effects of D-cycloserine and MK-801 on the performance of rats in two spatial learning and memory tasks. Eur Neuropsychopharmacol 5:457-463.
54. Pussinen R, Nieminen S, Koivisto E, Haapalinna A, Riekkinen P, Sr., Sirvio J (1997) Enhancement of intermediate-term memory by an alpha-1 agonist or a partial agonist at the glycine site of the NMDA receptor. Neurobiol Learn Mem 67:69-74.
55. Quartermain D, Mower J, Rafferty MF, Herting RL, Lanthorn TH (1994) Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol 257:7-12.
56. Raczka KA, Gartmann N, Mechias ML, Reif A, Buchel C, Deckert J, Kalisch R (2010) A neuropeptide S receptor variant associated with overinterpretation of fear reactions: a potential neurogenetic basis for catastrophizing. Mol Psychiatry 15:1045, 1067-1074.
57. Ravindran LN, Stein MB (2010) The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry 71:839-854.
58. Reinscheid RK, Xu YL, Civelli O (2005) Neuropeptide S: a new player in the modulation of arousal and anxiety. Mol Interv 5:42-46.
59. Ruzza C, Rizzi A, Trapella C, Pela M, Camarda V, Ruggieri V, Filaferro M, Cifani C, Reinscheid RK, Vitale G, Ciccocioppo R, Salvadori S, Guerrini R, Calo G (2010) Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68. Peptides 31:915-925.
60. Si W, Aluisio L, Okamura N, Clark SD, Fraser I, Sutton SW, Bonaventure P, Reinscheid RK (2010) Neuropeptide S stimulates dopaminergic neurotransmission in the medial prefrontal cortex. J Neurochem 115:475-482.
61. Singewald N, Schmuckermair C, Whittle N, Holmes A, Ressler KJ (2015) Pharmacology of cognitive enhancers for exposurebased therapy of fear, anxiety and trauma-related disorders. Pharmacol Ther 149:150-190.
62. Slattery D, Naik RR, Yen Y-C, Sartori SB, Fuechsl A, Finger BC, Elfving B, Nordemann U, Guerrini R, Calo G, Wegener W, Mathé AA, Singewald N, Czibere L, Landgraf R, Neumann ID (2015)
63. Selective breeding for high anxiety introduces a synonymous SNP that increases neuropeptide S receptor activity. J Neurosci in press. Smits JA, Rosenfield D, Otto MW, Powers MB, Hofmann SG, Telch MJ, Pollack MH, Tart CD (2013) D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiatry 73:1054-1058.
64. Spiegel DA, Bruce TJ (1997) Benzodiazepines and exposure-based cognitive behavior therapies for panic disorder: conclusions from combined treatment trials. Am J Psychiatry 154:773-781.
65. Stein DJ, Ipser J, McAnda N (2009) Pharmacotherapy of posttraumatic stress disorder: a review of meta-analyses and treatment guidelines. CNS Spectr 14:25-31.
66. Vervliet B, Craske MG, Hermans D (2013) Fear extinction and relapse: state of the art. Annual review of clinical psychology 9:215-248.
67. Vitale G, Filaferro M, Ruggieri V, Pennella S, Frigeri C, Rizzi A, Guerrini R, Calo G (2008) Anxiolytic-like effect of neuropeptide S in the rat defensive burying. Peptides 29:2286-2291.
68. Weber M, Hart J, Richardson R (2007) Effects of D-cycloserine on extinction of learned fear to an olfactory cue. Neurobiol Learn Mem 87:476-482.
69. Wegener G, Finger BC, Elfving B, Keller K, Liebenberg N, Fischer CW, Singewald N, Slattery DA, Neumann ID, Mathe AA (2012) Neuropeptide S alters anxiety, but not depression-like behaviour in Flinders Sensitive Line rats: a genetic animal model of depression. Int J Neuropsychopharmacol 15:375-387.
70. Whittle N, Hauschild M, Lubec G, Holmes A, Singewald N (2010) Rescue of impaired fear extinction and normalization of cortico-amygdala circuit dysfunction in a genetic mouse model by dietary zinc restriction. J Neurosci 30:13586-13596.
71. Whittle N, Schmuckermair C, Gunduz Cinar O, Hauschild M, Ferraguti F, Holmes A, Singewald N (2013) Deep brain stimulation, histone deacetylase inhibitors and glutamatergic drugs rescue resistance to fear extinction in a genetic mouse model. Neuropharmacology 64:414-423.
72. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R, Maercker A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen HC (2011) The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21:655-679.